Rashmi Kanagal-Shamanna

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1355244/publications.pdf

Version: 2024-02-01

160	7,219	81839	66879
papers	citations	39 h-index	78 g-index

167	167	167	7061
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/DendriticÂNeoplasms. Leukemia, 2022, 36, 1703-1719.	3.3	1,211
2	Ibrutinib and Venetoclax for First-Line Treatment of CLL. New England Journal of Medicine, 2019, 380, 2095-2103.	13.9	388
3	Complete Surgical Excision Is Essential for the Management of Patients With Breast Implantâ€“Associated Anaplastic Large-Cell Lymphoma. Journal of Clinical Oncology, 2016, 34, 160-168.	0.8	349
4	Breast Implantâ€“Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients. Journal of Clinical Oncology, 2014, 32, 114-120.	0.8	338
5	Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes. Journal of Molecular Diagnostics, 2013, 15, 607-622.	1.2	314
6	TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer, 2016, 122, 3484-3491.	2.0	200
7	Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Modern Pathology, 2014, 27, 314-327.	2.9	196
8	Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood, 2014, 123, 2645-2651.	0.6	192
9	Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica, 2014, 99, 465-473.	1.7	165
10	Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Research and Treatment, 2014, 147, 1-14.	1.1	131
11	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood, 2016, 127, 1269-1275.	0.6	119
12	Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leukemia Research, 2015, 39, 348-354.	0.4	115
13	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer, 2017, 123, 4391-4402.	2.0	114
14	Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Advances, 2020, 4, 5681-5689.	2.5	105
15	DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and highâ€risk disease. American Journal of Hematology, 2019, 94, 757-766.	2.0	86
16	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Advances, 2020, 4, 482-495.	2.5	86
17	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Advances, 2019, 3, 922-933.	2.5	84
18	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematology,the, 2019, 6, e29-e37.	2.2	84

#	Article	IF	Citations
19	Longâ€term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. British Journal of Haematology, 2018, 183, 578-587.	1.2	81
20	MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma. Advances in Anatomic Pathology, 2013, 20, 315-326.	2.4	72
21	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitorâ€"resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer, 2019, 125, 559-574.	2.0	70
22	Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer, 2020, 126, 765-774.	2.0	69
23	Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wildâ€typeTP53. Cancer, 2012, 118, 2879-2888.	2.0	68
24	Differential Expression of CD200 in B-Cell Neoplasms by Flow Cytometry Can Assist in Diagnosis, Subclassification, and Bone Marrow Staging. American Journal of Clinical Pathology, 2014, 142, 837-844.	0.4	66
25	Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica, 2017, 102, 1661-1670.	1.7	64
26	Advances in clinical next-generation sequencing: target enrichment and sequencing technologies. Expert Review of Molecular Diagnostics, 2016, 16, 357-372.	1.5	63
27	Crystalâ€storing histiocytosis: a clinicopathological study of 13 cases. Histopathology, 2016, 68, 482-491.	1.6	60
28	Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica, 2019, 104, 305-311.	1.7	56
29	Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood, 2022, 140, 1753-1763.	0.6	56
30	Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genetics in Medicine, 2022, 24, 986-998.	1.1	55
31	MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 37-48.	0.6	54
32	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) â€•outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patients. American Journal of Hematology, 2020, 95, 623-629.	2.0	54
33	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia. JAMA Oncology, 2021, 7, 1213.	3.4	53
34	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. American Journal of Hematology, 2020, 95, 612-622.	2.0	51
35	Fourâ€year followâ€up of a single arm, phase <scp>II</scp> clinical trial of ibrutinib with rituximab (<scp>IR</scp>) in patients with relapsed/refractory mantle cell lymphoma (<scp>MCL</scp>). British Journal of Haematology, 2018, 182, 404-411.	1.2	50
36	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. Blood Cancer Discovery, 2021, 2, 125-134.	2.6	50

#	Article	IF	Citations
37	Digital PCR: Principles and Applications. Methods in Molecular Biology, 2016, 1392, 43-50.	0.4	48
38	TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood, 2022, 140, 58-72.	0.6	46
39	Highâ€grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. Histopathology, 2012, 61, 945-954.	1.6	44
40	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Advances, 2020, 4, 1038-1050.	2.5	43
41	Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget, 2016, 7, 14251-14258.	0.8	42
42	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 2022, 40, 3848-3857.	0.8	41
43	Outcomes in patients with newly diagnosed TP53â€mutated acute myeloid leukemia with or without venetoclaxâ€based therapy. Cancer, 2021, 127, 3541-3551.	2.0	40
44	Improving the detection of patients with inherited predispositions to hematologic malignancies using nextâ€generation sequencingâ€based leukemia prognostication panels. Cancer, 2018, 124, 2704-2713.	2.0	39
45	Classical Hodgkin Lymphoma Arising in the Setting of Iatrogenic Immunodeficiency. American Journal of Surgical Pathology, 2013, 37, 1290-1297.	2.1	38
46	Leukemic Involvement in the Thorax. Radiographics, 2019, 39, 44-61.	1.4	38
47	High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Advances, 2022, 6, 4006-4014.	2.5	37
48	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Advances, 2018, 2, 1807-1816.	2.5	34
49	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. Journal of Clinical Oncology, 2022, 40, 202-212.	0.8	34
50	Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. Expert Review of Molecular Diagnostics, 2016, 16, 461-472.	1.5	33
51	The absolute percent deviation of <scp>IGHV</scp> mutation rather than a 98% cutâ€off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. British Journal of Haematology, 2018, 180, 33-40.	1.2	33
52	Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Frontiers in Oncology, 2020, 10, 582213.	1.3	33
53	Prognostic factors for progression in patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer, 2021, 127, 2648-2656.	2.0	33
54	Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Human Pathology, 2013, 44, 110-121.	1.1	31

#	Article	IF	Citations
55	Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. Modern Pathology, 2018, 31, 1717-1732.	2.9	30
56	Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation. Human Pathology, 2012, 43, 1828-1838.	1.1	29
57	Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. American Journal of Hematology, 2020, 95, 227-229.	2.0	29
58	Nucleophosmin 1 Mutations in Acute Myeloid Leukemia. Genes, 2020, 11, 649.	1.0	29
59	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1â€mutated acute myeloid leukaemia. British Journal of Haematology, 2021, 192, 1054-1063.	1.2	28
60	Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia. Cancer Genetics, 2018, 228-229, 236-250.	0.2	26
61	Association of gene mutations with timeâ€toâ€first treatment in 384 treatmentâ€naive chronic lymphocytic leukaemia patients. British Journal of Haematology, 2019, 187, 307-318.	1.2	26
62	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 2022, 28, 557-567.	15.2	26
63	Differential expression of aurora-A kinase in T-cell lymphomas. Modern Pathology, 2013, 26, 640-647.	2.9	25
64	Therapy-Related Myeloid Neoplasms. American Journal of Clinical Pathology, 2015, 144, 207-218.	0.4	25
65	Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. Cancer Genetics, 2018, 228-229, 197-217.	0.2	25
66	Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Advances, 2020, 4, 1670-1677.	2.5	24
67	Longâ€term followâ€up of salvage therapy using a combination of inotuzumab ozogamicin and miniâ€“hyperâ€CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia. Cancer, 2021, 127, 2025-2038.	2.0	24
68	Ultra-Rapid Reporting of GENomic Targets (URGENTseq). Journal of Molecular Diagnostics, 2019, 21, 89-98.	1.2	23
69	Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood, 2015, 125, 3360-3363.	0.6	22
70	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia, 2021, 35, 3421-3429.	3.3	22
71	Ibrutinibâ€“rituximab followed by R-HCVAD as frontline treatment for young patients (â‰¤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncology, The, 2022, 23, 406-415.	5.1	22
72	Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. Cancer Genetics, 2018, 228-229, 218-235.	0.2	21

#	Article	IF	Citations
73	Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent <scp>CD</scp>33 expression and in vitro response to targeted <scp>CD</scp>33 therapy. British Journal of Haematology, 2019, 186, 538-548.	1.2	21
74	Quantitative Assessment of Mutant Allele Burden in Solid Tumors by Semiconductor-Based Next-Generation Sequencing. American Journal of Clinical Pathology, 2014, 141, 559-572.	0.4	20
75	Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. Modern Pathology, 2015, 28, 1014-1022.	2.9	20
76	Outcomes with lower intensity therapy inTP53-mutated acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2238-2241.	0.6	20
77	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer Journal, 2020, 10, 61.	2.8	20
78	Optical genome mapping for structural variation analysis in hematologic malignancies. American Journal of Hematology, 2022, 97, 975-982.	2.0	20
79	Clonal hematopoiesis of indeterminate potentialâ€“associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer, 2019, 125, 2233-2241.	2.0	19
80	Routine sequencing in <scp>CLL</scp> has prognostic implications and provides new insight into pathogenesis and targeted treatments. British Journal of Haematology, 2019, 185, 852-864.	1.2	19
81	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. American Journal of Hematology, 2021, 96, 241-250.	2.0	19
82	Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer, 2021, 127, 3552-3565.	2.0	19
83	TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyperâ€CVADâ€based regimens. Cancer, 2017, 123, 3717-3724.	2.0	18
84	TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Annals of Diagnostic Pathology, 2019, 41, 38-42.	0.6	18
85	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapseâ€free survival. American Journal of Hematology, 2018, 93, 1376-1383.	2.0	17
86	Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q). Cancer Genetics, 2013, 206, 42-46.	0.2	16
87	Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Modern Pathology, 2020, 33, 1678-1689.	2.9	16
88	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 1494-1499.	3.3	16
89	LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leukemia and Lymphoma, 2020, 61, 1493-1499.	0.6	14
90	Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. Cancer Genetics, 2020, 243, 52-72.	0.2	14

#	Article	IF	Citations
91	Utility of Quantitative Flow Cytometry Immunophenotypic Analysis of CD5 Expression in Small B-Cell Neoplasms. Archives of Pathology and Laboratory Medicine, 2014, 138, 903-909.	1.2	13
92	Longâ€term results of lowâ€intensity chemotherapy with clofarabine or cladribine combined with lowâ€dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2021, 96, 914-924.	2.0	13
93	Emulsion PCR: Techniques and Applications. Methods in Molecular Biology, 2016, 1392, 33-42.	0.4	13
94	A heavy metal baseline score predicts outcome in acute myeloid leukemia. American Journal of Hematology, 2020, 95, 422-434.	2.0	12
95	Advances in B-lymphoblastic leukemia: cytogenetic and genomic lesions. Annals of Diagnostic Pathology, 2016, 23, 43-50.	0.6	11
96	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. Blood, 2020, 136, 42-43.	0.6	11
97	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3 â€ITD and IDH mutations. Cancer, 2021, 127, 381-390.	2.0	10
98	Development of <scp>TP53</scp> mutations over the course of therapy for acute myeloid leukemia. American Journal of Hematology, 2021, 96, 1420-1428.	2.0	10
99	Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2020, 136, 17-19.	0.6	10
100	Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Modern Pathology, 2022, 35, 1212-1219.	2.9	10
101	RAS and TP53 can predict survival in adults with Tâ€cell lymphoblastic leukemia treated with hyperâ€CVAD. Cancer Medicine, 2020, 9, 849-858.	1.3	9
102	Impact of <scp>CD33</scp> and <scp>ABCB1</scp> single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. American Journal of Hematology, 2020, 95, E225-E228.	2.0	9
103	Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience. Modern Pathology, 2021, 34, 854-861.	2.9	9
104	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (<scp>MDS/MPNâ€RSâ€T</scp>) and myelodysplastic syndrome with ring sideroblasts (<scp>MDSâ€RS</scp>). American Journal of Hematology, 2021, 96, E246-E249.	2.0	9
105	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Modern Pathology, 2021, , .	2.9	9
106	Clinical characteristics and outcomes of previously untreated patients with adult onset Tâ€cell acute lymphoblastic leukemia and Tâ€lymphoblastic lymphoma with hyperâ€CVAD based regimens. American Journal of Hematology, 2017, 92, E595-E597.	2.0	8
107	Synchronous presentation of intraâ€nodal follicular dendritic cell sarcoma and Castleman disease. American Journal of Hematology, 2017, 92, 478-479.	2.0	8
108	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. American Journal of Hematology, 2021, 96, E50-E53.	2.0	8

#	Article	IF	Citations
109	Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer Journal, 2021, 11, 18.	2.8	8
110	Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplantation, 2022, 57, 370-376.	1.3	8
111	Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens. Leukemia Research, 2019, 84, 106176.	0.4	7
112	Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases. Leukemia and Lymphoma, 2019, 60, 1568-1571.	0.6	7
113	Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies. Current Hematologic Malignancy Reports, 2020, 15, 194-202.	1.2	7
114	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. Modern Pathology, 2021, 34, 2183-2191.	2.9	7
115	Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies. Frontiers in Oncology, 2021, 11, 748250.	1.3	7
116	Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. American Journal of Clinical Pathology, 2016, 145, 418-427.	0.4	6
117	Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia â€“ a distinct subtype with favorable prognosis. Leukemia and Lymphoma, 2021, 62, 224-228.	0.6	6
118	Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. American Journal of Hematology, 2021, 96, E137-E140.	2.0	6
119	The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition. Current Hematologic Malignancy Reports, 2021, 16, 336-344.	1.2	6
120	TP53â€altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitorâ€based therapy: A retrospective analysis. American Journal of Hematology, 2022, 97, 1005-1012.	2.0	6
121	Phenotypic evolution in a case of peripheral Tâ€cell lymphoma suggests the presence of tumor heterogeneity. Journal of Cutaneous Pathology, 2013, 40, 573-579.	0.7	5
122	Systemic AL amyloidosis associated with WaldenstrÃ¶m macroglobulinemia: an unusual presenting complication. Blood, 2016, 127, 168-168.	0.6	5
123	Validation of the 2016 revisions to the <scp>WHO</scp> classification in lowerâ€risk myelodysplastic syndrome. American Journal of Hematology, 2017, 92, E168-E171.	2.0	5
124	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer Journal, 2021, 11, 52.	2.8	5
125	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer, 2021, 127, 3113-3124.	2.0	5
126	Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia, 2022, 36, 1189-1192.	3.3	5

#	Article	IF	Citations
127	Over-Expression of CYP2E1 mRNA and Protein: Implications of Xenobiotic Induced Damage in Patients with De Novo Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFÎ²-MYH11. International Journal of Environmental Research and Public Health, 2012, 9, 2788-2800.	1.2	4
128	Characterization of TP53 mutations in clonal cytopenia of undetermined significance. American Journal of Hematology, 2017, 92, E175-E177.	2.0	4
129	Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. Current Hematologic Malignancy Reports, 2018, 13, 467-476.	1.2	4
130	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. American Journal of Hematology, 2020, 95, E313-E315.	2.0	4
131	Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leukemia Research, 2021, 101, 106511.	0.4	4
132	Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies. Blood, 2018, 132, 1798-1798.	0.6	4
133	Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases. Human Pathology, 2021, 118, 60-68.	1.1	4
134	Donor-derived isolated del(20q) after hematopoietic stem cell transplantation: report of two cases and review of the literature. Journal of Hematopathology, 2013, 6, 25-32.	0.2	3
135	Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult Bâ€cell acute lymphoblastic leukemia (Bâ€ALL) with TET2 and TP53 mutations. American Journal of Hematology, 2016, 91, 354-355.	2.0	3
136	Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. Leukemia and Lymphoma, 2020, 61, 2980-2984.	0.6	3
137	<scp>FLT3</scp> inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed <scp>Acute Myeloid Leukemia</scp> with very low <scp>FLT3</scp> allelic burden. American Journal of Hematology, 2021, 96, E275-E279.	2.0	3
138	A community approach to the cancer-variant-interpretation bottleneck. Nature Cancer, 2022, 3, 522-525.	5.7	3
139	Targeted therapyâ€“induced differentiation of acute myeloid leukemia blasts. Blood, 2017, 129, 3503-3503.	0.6	2
140	Refractory hairy cell leukemiaâ€variant. American Journal of Hematology, 2017, 92, 1398-1399.	2.0	2
141	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). American Journal of Hematology, 2020, 95, E326-E329.	2.0	2
142	Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia. Leukemia Research, 2021, 108, 106616.	0.4	2
143	Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series. Blood, 2020, 136, 18-19.	0.6	2
144	Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab. Blood, 2020, 136, 31-32.	0.6	2

#	Article	IF	Citations
145	Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors - Comprehensive Analysis of 396 Patients. Blood, 2020, 136, 32-33.	0.6	2
146	Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia, 2022, 36, 2097-2107.	3.3	2
147	Metastatic rhabdomyosarcoma initially diagnosed on the bone marrow. Blood, 2016, 128, 2189-2189.	0.6	1
148	Rational â€œError Eliminationâ€•Approach to Evaluating Molecular Barcoded Next-Generation Sequencing Data Identifies Low-Frequency Mutations in Hematologic Malignancies. Journal of Molecular Diagnostics, 2019, 21, 471-482.	1.2	1
149	Clonal Hematopoiesis and Its Implications for Flow Cytometric Assessment of Measurable Residual Disease in Patients with NPM1-mutated Acute Myeloid Leukemia. Blood, 2020, 136, 38-39.	0.6	1
150	<scp>Nonâ€coding NOTCH1</scp> mutations in chronic lymphocytic leukemia negatively impact prognosis. American Journal of Hematology, 2022, 97, .	2.0	1
151	Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leukemia Research, 2022, 116, 106827.	0.4	1
152	Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy. Blood Advances, 2023, 7, 828-831.	2.5	1
153	Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups. Blood, 2020, 136, 20-22.	0.6	0
154	Hypomethylating Agents Do Not Alter Novel Splicing Events in Myeloid Neoplasms. Blood, 2020, 136, 37-38.	0.6	0
155	Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression. Blood, 2020, 136, 19-20.	0.6	0
156	Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma. Blood, 2020, 136, 41-42.	0.6	0
157	Expert Variant Curation Combined with in-Silico analysis for Clinical Interpretation of BCL2 variants in Resistance to BCL2 Inhibitors in Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma. Blood, 2020, 136, 42-43.	0.6	0
158	Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT). Blood, 2020, 136, 23-23.	0.6	0
159	Molecular characterization of Novel ATM fusions in chronic lymphocytic leukemia and T-cell prolymphocytic leukemia. Leukemia and Lymphoma, 2021, , 1-11.	0.6	0
160	Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Modern Pathology, 0, , .	2.9	0